权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

CELL EVALUATION & THERAPY

细胞评估

基本信息

批准号：
9248291
负责人：
GUSTAVO WALTER LEONE
金额：
$ 9.06万
依托单位：
MEDICAL UNIVERSITY OF SOUTH CAROLINA
依托单位国家：
美国
项目类别：
财政年份：
2017
资助国家：
美国
起止时间：
2017-04-01 至 2019-03-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9248291
关键词：
Alpha Cell Apoptosis Biological Assay Biological Response Modifier Therapy Cancer Center Cancer Center Support Grant Cell Cycle Cell Proliferation Cell Separation Cell Therapy Cell surface Cells Clinical Clinical Research Consultations Cyclic GMP Data Data Analyses Detection Development Doctor of Philosophy Equipment Experimental Designs Flow Cytometry Funding Goals Healthcare Human Immune response Immunologic Monitoring Immunophenotyping Instruction Lasers Malignant Neoplasms Measurement Medical Membrane Methodology Methods Mission Patients Peer Review Phase Population Preparation Proteins Publications Regulation Research Research Personnel Research Project Grants Resource Sharing Sampling Services Side South Carolina Speed Staining method Stains Technology Therapy Evaluation Tissues Training Translational Research Universities base cell preparation cost effective experimental study gene therapy innovation laboratory experiment manufacturing facility member novel pre-clinical success

项目摘要

The Hollings Cancer Center (HCC) Cell Evaluation & Therapy (CET) Shared Resource offers HCC investigators comprehensive analytic flow cytometry and high-speed cell sorting services and the capacity to generate human cellular and tissue-based products for use in translational research. The mission of the CET Shared Resource is to provide an integrated platform where HCC users can evaluate pre-clinical or clinical experimental data in a cell-specific manner and use the cell-manufacturing facility to bring the cellular product to patients. Directed by Kevin F. Staveley-O'Carroll, MD, PhD, with two Associate Directors, Amanda C. LaRue, PhD and Shikhar Mehrotra, PhD, this facility provides extensive expertise, an active educational platform, and development of new methodologies within the facility. The specific objectives of the HCC CET Shared Resource are to provide: • Multi-parametric and multi-laser measurements including apoptosis, cell proliferation, cell cycle distribution, and immunophenotyping, as well as detection of intracellular proteins, membrane perturbations, and bioactive molecules. • Expanded cell therapy and gene therapy-based bio-therapeutic products for Phase I and II clinical studies employing current cGMP as required by federal regulations. • Immune monitoring services to evaluate the immune response in patients and provide data for basic laboratory experiments. • Regulatory expertise in the preparation of cell and possibly gene therapy based INDs. • High-speed cell sorting based on cell surface marker immunostaining and/or side-population staining. • Consultation and assistance concerning experimental design, sample preparation, and data analysis. • Training in the use of routine flow cytometric technology and analytical equipment. • Advanced training in novel flow cytometric assays that are new and/or specific to HCC researchers' applications. • New methods to assist HCC members in performing cutting-edge research. CET-supported experiments during the current CCSG project period have led to the success of more than 18 NCI-funded research project grants and more than 100 peer-reviewed publications.

Hollings癌症中心（HCC）细胞评估和治疗（CET）共享资源提供HCC 研究人员全面的分析流式细胞仪和高速细胞分选服务，并有能力生成用于转化研究的基于人类细胞和组织的产品。联合国的使命 CET共享资源旨在提供一个集成平台，HCC用户可以在其中评估临床前或临床实验数据，并使用细胞制造设施，使细胞产品给患者。导演：Kevin F. Staveley-O'Carroll，MD，PhD，with two Associate Directors，阿曼达C. LaRue博士和Shikhar Mehrotra博士，该设施提供广泛的专业知识，教育平台，并在设施内开发新的方法。 HCC CET共享资源的具体目标是提供： ·多参数和多激光测量，包括细胞凋亡、细胞增殖、细胞周期分布和免疫表型，以及检测细胞内蛋白，膜扰动和生物活性分子。 ·扩大细胞治疗和基因治疗为基础的生物治疗产品的I期和II期临床根据联邦法规要求，采用现行cGMP的研究。 ·免疫监测服务，以评估患者的免疫反应，并为基本的实验室实验 ·在制备基于细胞和可能的基因治疗的IND方面的监管专业知识。 ·基于细胞表面标记免疫染色和/或侧群染色的高速细胞分选。 ·关于实验设计、样品制备和数据分析的咨询和协助。 ·关于使用常规流式细胞技术和分析设备的培训。 ·在新的和/或特定于HCC研究人员的新型流式细胞术检测方面的高级培训应用. ·帮助HCC成员进行尖端研究的新方法。在当前CCSG项目期间，CET支持的实验已经成功地完成了18个以上的项目。 NCI资助的研究项目赠款和100多篇同行评审的出版物。